{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:31:16Z","timestamp":1777617076469,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["Novartis Pharma"],"award-info":[{"award-number":["Novartis Pharma"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Near Visual Acuity Questionnaire Presbyopia (NAVQ-P) is a patient-reported outcome (PRO) measure that was developed in a phakic presbyopia population to assess near vision function impacts. The study refined and explored the psychometric properties and score interpretability of the NAVQ-P and additional PRO items assessing near vision correction independence (NVCI), near vision satisfaction (NVS), and near vision correction preference (NVCP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a psychometric validation study conducted using PRO data collected as part of a Phase IIb clinical trial (CUN8R44 A2202) consisting of 235 randomized adults with presbyopia from the US, Japan, Australia, and Canada. Data collected at baseline, week 2, and months 1, 2, and 3 during the 3-month trial treatment period were included in the analyses to assess item (question) properties, NAVQ-P dimensionality and scoring, reliability, validity, and score interpretation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Item responses were distributed across the full response scale for most NAVQ-P and additional PRO items. Confirmatory factor analysis supported the pre-defined unidimensional structure and calculation of a NAVQ-P total score as a measure of near vision function. Item deletion informed by item response distributions, dimensionality analyses, item response theory, and previous qualitative findings, including clinical input, supported retention of 14 NAVQ-P items. The 14-item NAVQ-P total score had excellent internal consistency (\u03b1\u2009=\u20090.979) and high test-retest reliability (Intraclass Correlation Coefficients\u2009&gt;\u2009=\u20090.898). There was good evidence of construct-related validity for all PROs supported by strong correlations with concurrent measures. Excellent results for known-groups validity and ability to detect change analyses were also demonstrated. Anchor-based and distribution-based methods supported interpretation of scores through generation of group-level and within-individual estimates of meaningful change thresholds. A meaningful within-patient change in the range of 8-15-point improvement on the NAVQ-P total score (score range 0\u201342) was recommended, including a more specific responder definition of 10-point improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The NAVQ-P, NVCI, and NVS are valid and reliable instruments which have the ability to detect change over time. Findings strongly support the use of these measures as outcome assessments in clinical\/research studies and in clinical practice in the presbyopia population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00717-9","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:02:23Z","timestamp":1712646143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Psychometric evaluation of the near activity visual questionnaire presbyopia (NAVQ-P) and additional patient-reported outcome items"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-2186","authenticated-orcid":false,"given":"Joel","family":"Sims","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Sloesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Naujoks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Arbuckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Chiva-Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Pascoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Stochl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Findley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Wolffsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"717_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.preteyeres.2018.09.004","volume":"68","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn JS, Davies LN (2019) Presbyopia: effectiveness of correction strategies. Prog Retin Eye Res 68:124\u2013143","journal-title":"Prog Retin Eye Res"},{"key":"717_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-021-00379-x","volume":"5","author":"S Bentley","year":"2021","unstructured":"Bentley S, Findley A, Chiva-Razavi S, Naujoks C, Patalano F, Johnson C, Arbuckle R, Wolffsohn JS (2021) Evaluation of the content validity of patient-reported outcome (PRO) instruments developed for use with individuals with phakic presbyopia, including the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) and the near vision correction independence (NVCI) instrument. J patient-reported Outcomes 5:1\u201316","journal-title":"J patient-reported Outcomes"},{"issue":"1","key":"717_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-021-00383-1","volume":"5","author":"S Bentley","year":"2021","unstructured":"Bentley S, Findley A, Chiva-Razavi S, Naujoks C, Patalano F, Johnson C, Arbuckle R, Wolffsohn JS (2021) Understanding the visual function symptoms and associated functional impacts of phakic presbyopia. J Patient-Reported Outcomes 5(1):1\u201315","journal-title":"J Patient-Reported Outcomes"},{"issue":"9","key":"717_CR4","doi-asserted-by":"publisher","first-page":"e18306","DOI":"10.2196\/18306","volume":"22","author":"JS Wolffsohn","year":"2020","unstructured":"Wolffsohn JS, Leteneux-Pantais C, Chiva-Razavi S, Bentley S, Johnson C, Findley A, Tolley C, Arbuckle R, Kommineni J, Tyagi N (2020) Social media listening to Understand the Lived experience of Presbyopia: systematic search and content analysis study. J Med Internet Res 22(9):e18306","journal-title":"J Med Internet Res"},{"key":"717_CR5","unstructured":"Opthalmology AAo (2017) What is Presbyopia?; https:\/\/www.aao.org\/eye-health\/diseases\/what-is-presbyopia"},{"key":"717_CR6","doi-asserted-by":"crossref","unstructured":"Berdahl J, Bala C, Dhariwal M, Lemp-Hull J, Thakker D, Jawla S (2020) Patient and economic burden of presbyopia: a systematic literature review. Clin Ophthalmol:3439\u20133450","DOI":"10.2147\/OPTH.S269597"},{"issue":"3","key":"717_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/APO.0000000000000297","volume":"9","author":"A Grzybowski","year":"2020","unstructured":"Grzybowski A, Markeviciute A, Zemaitiene R (2020) A review of pharmacological presbyopia treatment. Asia-pacific J Ophthalmol (Philadelphia Pa) 9(3):226","journal-title":"Asia-pacific J Ophthalmol (Philadelphia Pa)"},{"issue":"1","key":"717_CR8","doi-asserted-by":"publisher","first-page":"e000453","DOI":"10.1136\/bmjophth-2020-000453","volume":"5","author":"G Sharma","year":"2020","unstructured":"Sharma G, Chiva-Razavi S, Viriato D, Naujoks C, Patalano F, Bentley S, Findley A, Johnson C, Arbuckle R, Wolffsohn J (2020) Patient-reported outcome measures in presbyopia: a literature review. BMJ open Ophthalmol 5(1):e000453","journal-title":"BMJ open Ophthalmol"},{"key":"717_CR9","doi-asserted-by":"crossref","unstructured":"Paley GL, Chuck RS, Tsai LM (2016) Corneal-based surgical presbyopic therapies and their application in pseudophakic patients. Journal of ophthalmology 2016","DOI":"10.1155\/2016\/5263870"},{"issue":"1","key":"717_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jcrs.2011.07.032","volume":"38","author":"PJ Buckhurst","year":"2012","unstructured":"Buckhurst PJ, Wolffsohn JS, Gupta N, Naroo SA, Davies LN, Shah S (2012) Development of a questionnaire to assess the relative subjective benefits of presbyopia correction. J Cataract Refractive Surg 38(1):74\u201379","journal-title":"J Cataract Refractive Surg"},{"key":"717_CR11","doi-asserted-by":"publisher","unstructured":"Grzybowski A, Ruamviboonsuk V (2022) Pharmacological treatment in Presbyopia. J Clin Med 11(5). https:\/\/doi.org\/10.3390\/jcm11051385","DOI":"10.3390\/jcm11051385"},{"issue":"1","key":"717_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcrs.2009.07.034","volume":"36","author":"K Hayashi","year":"2010","unstructured":"Hayashi K, Yoshida M, Manabe S-i, Hayashi H (2010) Comparison of visual function between phakic eyes and pseudophakic eyes with a monofocal intraocular lens. J Cataract Refractive Surg 36(1):20\u201327. https:\/\/doi.org\/10.1016\/j.jcrs.2009.07.034","journal-title":"J Cataract Refractive Surg"},{"key":"717_CR13","unstructured":"US Food and Drug Administration (2022) Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. Guidance for Industry. Food and Drug Administration staff, and other stakeholders"},{"key":"717_CR14","unstructured":"US Food and Drug Administration (2022) Patient-focused drug development: Selecting, developing, or modifying fit-for purpose clinical outcome assessments (draft guidance) Food and Drug Administration staff, and other stakeholders draft guidance"},{"key":"717_CR15","volume-title":"Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products","author":"Committee for Medicinal Products for Human Use","year":"2005","unstructured":"Committee for Medicinal Products for Human Use (2005) Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency, London"},{"key":"717_CR16","unstructured":"Food and Drug Administration (2009) Patient-reported outcome measures: use in Medical Product Development to support labeling claims. Guidance for Industry"},{"key":"717_CR17","unstructured":"Cary NU (2015) SAS institute Inc [computer program] Version 9.4"},{"key":"717_CR18","volume-title":"Test theory: a unified treatment","author":"RP McDonald","year":"1999","unstructured":"McDonald RP (1999) Test theory: a unified treatment. L. Erlbaum Associates, Mahwah, N.J"},{"issue":"2","key":"717_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/014662168400800201","volume":"8","author":"WM Yen","year":"1984","unstructured":"Yen WM (1984) Effects of local item dependence on the fit and equating performance of the three-parameter logistic model. Appl Psychol Meas 8(2):125\u2013145","journal-title":"Appl Psychol Meas"},{"issue":"1","key":"717_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-018-0997-5","volume":"16","author":"S Cano","year":"2018","unstructured":"Cano S, Chrea C, Salzberger T, Alfieri T, Emilien G, Mainy N, Ramazzotti A, L\u00fcdicke F, Weitkunat R (2018) Development and validation of a new instrument to measure perceived risks associated with the use of tobacco and nicotine-containing products. Health Qual Life Outcomes 16(1):1\u201315","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"717_CR21","first-page":"95","volume":"9","author":"D Andrich","year":"1982","unstructured":"Andrich D (1982) An index of person separation in latent trait theory, the traditional KR. 20 index, and the Guttman scale response pattern. Educ Res Perspect 9(1):95\u2013104","journal-title":"Educ Res Perspect"},{"key":"717_CR22","doi-asserted-by":"crossref","unstructured":"Fayers P, Machin D (2007) Quality of Life: The assessment, analysis and interpretation of patient-reported outcomes","DOI":"10.1002\/9780470024522"},{"issue":"8","key":"717_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jcrs.2009.03.026","volume":"35","author":"N Gupta","year":"2009","unstructured":"Gupta N, Wolffsohn JS, Naroo SA (2009) Comparison of near visual acuity and reading metrics in presbyopia correction. J Cataract Refract Surg 35(8):1401\u20131409. https:\/\/doi.org\/10.1016\/j.jcrs.2009.03.026","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"717_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102\u2013109","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"717_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-4-70","volume":"4","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK (2006) Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 4(1):70","journal-title":"Health Qual Life Outcomes"},{"key":"717_CR26","unstructured":"Harper A, Trennery C, Sully K, Trigg A Triangulating estimates of meaningful change or difference in patient-reported outcomes: application of a correlation-based weighting procedure. In: QUALITY OF LIFE RESEARCH, 2018. SPRINGER VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS, pp S17-S17"},{"issue":"10","key":"717_CR27","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s11136-021-02957-4","volume":"30","author":"A Trigg","year":"2021","unstructured":"Trigg A, Griffiths P (2021) Triangulation of multiple meaningful change thresholds for patient-reported outcome scores. Qual Life Res 30(10):2755\u20132764. https:\/\/doi.org\/10.1007\/s11136-021-02957-4","journal-title":"Qual Life Res"},{"issue":"3","key":"717_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/OPX.0b013e3180339f30","volume":"84","author":"N McClenaghan","year":"2007","unstructured":"McClenaghan N, Kimura A, Stark LR (2007) An evaluation of the M&S technologies smart system II for visual acuity measurement in young visually-normal adults. Optom Vis Sci 84(3):218\u2013223","journal-title":"Optom Vis Sci"},{"key":"717_CR29","first-page":"11","volume-title":"Repeatability of Tablet Computer - based Near Visual Acuity Measurement","author":"L Sparschu","year":"2017","unstructured":"Sparschu L, Pang Y, Nylin E (2017) Repeatability of Tablet Computer - based Near Visual Acuity Measurement. In: American Academy of Optometry, Chicago, IL, pp 11\u201314"},{"key":"717_CR30","volume-title":"Psychometric theory","author":"I Bernstein","year":"1994","unstructured":"Bernstein I (1994) Psychometric theory, 3rd edn. McGraw Hill, New York, NY, US","edition":"3"},{"key":"717_CR31","unstructured":"Fleiss JL, Levin B, Paik MC (2013) Statistical methods for rates and proportions. Wiley"},{"key":"717_CR32","doi-asserted-by":"crossref","unstructured":"Cohen J (2013) Statistical power analysis for the behavioral sciences. Hoboken. NJ: Taylor and Francis https:\/\/doi org\/10 4324 (9780):2","DOI":"10.4324\/9780203771587"},{"key":"717_CR33","unstructured":"US Food and Drug Administration (2023) Patient-focused Drug Development: incorporating clinical outcome assessments into endpoints for Regulatory Decision-Making. Draft Guidance for Industry, Food and Drug Administration Staff, and other stakeholders. Food and Drug Administration, Patient-Focused Drug Development Guidance Series"},{"issue":"5","key":"717_CR34","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s11136-022-03286-w","volume":"32","author":"P Griffiths","year":"2023","unstructured":"Griffiths P, Sims J, Williams A, Williamson N, Cella D, Brohan E, Cocks K (2023) How strong should my anchor be for estimating group and individual level meaningful change? A simulation study assessing anchor correlation strength and the impact of sample size, distribution of change scores and methodology on establishing a true meaningful change threshold. Qual Life Res 32(5):1255\u20131264. https:\/\/doi.org\/10.1007\/s11136-022-03286-w","journal-title":"Qual Life Res"},{"issue":"2","key":"717_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD (2011) Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev PharmacoEcon Outcomes Res 11(2):163\u2013169","journal-title":"Expert Rev PharmacoEcon Outcomes Res"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00717-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:07:15Z","timestamp":1712646435000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00717-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00717-9","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"41"}}